Table 7.
Rank order of melanoma in males (decreasing) compared to the rank order (decreasing) of antibiotic consumptions of “promoting” and the rank order (increasing) of “inhibitor” effect of antibiotics. Eight countries with the highest consumption of “promoting” antibiotics included in the first ten highest incidences of melanoma (males) countries. Eight of ten countries with the lowest consumption of “inhibitory” antibiotics are included in the first ten countries with the highest incidence of melanoma (males).
| Incidence of Melanoma (Male) in Decreasing Rank Order | Rank Order (Decreasing) of Antibiotics with Possible “Promoting” Effect on the Development of Lung Cancer | Incidence of Melanoma (Male) in Decreasing Rank Order | Rank Order (Increasing) of Antibiotics with Possible “Inhibiting” Effect on the Development of Melanoma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Countries | New Cases/100,000 Inhabitants. 2018 | Countries | J01A | Countries | J01CE + CF | Countries | New Cases/ 100,000 Inhabitants2018 |
Countries | J01CA + CR (%) | Countries | J01D (%) | Countries | J01M (%) |
| Norway | 41.1 | United Kingdom | 25.78 | Denmark | 41.03 | Norway | 41.1 | Sweden | 8.17 | Denmark | 0.2 | Denmark | 3.37 |
| Netherlands | 37 | Netherlands | 25.57 | Sweden | 38.21 | Netherlands | 37 | Norway | 12.68 | Norway | 0.6 | Norway | 3.42 |
| Sweden | 32.9 | Iceland | 25.46 | Norway | 27.58 | Sweden | 32.9 | Germany | 19.03 | United Kingdom | 1.02 | United Kingdom | 3.622 |
| Denmark | 30.3 | Finland | 23.89 | Iceland | 18.94 | Denmark | 30.3 | Finland | 20.37 | Iceland | 2.32 | Iceland | 4.19 |
| Germany | 26.9 | Latvia | 22.15 | Slovenia | 16.76 | Germany | 26.9 | Denmark | 21.34 | Ireland | 2.57 | Ireland | 5.01 |
| Luxembourg | 24.9 | Sweden | 22.01 | Slovakia | 13.54 | Luxembourg | 24.9 | Czech Republic | 22.36 | Finland | 3.83 | Finland | 5.31 |
| Slovenia | 24.7 | Germany | 20.99 | Czech Rep | 13.19 | Slovenia | 24.7 | Slovenia | 23.52 | Sweden | 3.965 | Sweden | 6.23 |
| Finland | 22.9 | Estonia | 20.8 | United Kingdom | 12.008 | Finland | 22.9 | Netherland | 24.17 | Lithuania | 4.87 | Lithuania | 6.74 |
| Belgium | 21.6 | Norway | 19.38 | Ireland | 11.04 | Belgium | 21.6 | Slovakia | 25.62 | Poland | 8.29 | Poland | 6.82 |
| United Kingdom | 21.2 | Czech Republic | 15.12 | Finland | 9.62 | United Kingdom | 21.2 | Greece | 26.17 | Czech Republic | 8.49 | Czech Rep | 7.36 |
J01A—tetracycline; J01CE—narrow-spectrum, beta-lactamase sensitive penicillin; J01CF—narrow-spectrum, beta-lactamase-resistant penicillin; J01CA—broad-spectrum, beta-lactamase sensitive penicillin; J01CR—broad-spectrum, beta-lactamase inhibitor penicillin; J01D—cephalosporin; J01M—quinolone.